"Intravenous Vaccination Promotes Brain Plasticity and Prevents Memory Loss in Alzheimer's Disease"
Alzheimer's disease (AD) is an incurable, progressive neurodegenerative disease affecting over five million people worldwide, and is the leading cause of dementia in the elderly. Currently, intravenous human immunoglobulin (IVIG) treatment is being explored in multiple off-label uses other than immunotherapy, including AD. Several clinical studies assessing the tolerability and efficacy of IVIG in Alzheimer's disease subjects are in progress with inconsistent outcomes. Recent studies conducted by Dr. Giulio Maria Pasinetti, Saunders Family Chair and Professor in Neurology and Psychiatry at Mount Sinai School of Medicine, suggests that the divergent outcomes in Alzheimer's disease clinical studies of IVIG may be due to differences in temporal administration and administered dosages. "This experimental observation provides a rational basis for rectifying the inconsistency of study outcomes in Alzheimer's disease clinical trials with IVIG," said Dr. Pasinetti. Learn more
Mount Sinai Launches AI Small Molecule Drug Discovery Center
Apr 02, 2025 View All Press Releases
